1043 results about "Inflammatory bowel disease" patented technology

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention relates to the field of biomedical materials, and particularly discloses a manganese dioxide nano-enzyme for treating inflammatory bowel disease as well as a preparation method and application of the manganese dioxide nano-enzyme. The preparation method of the manganese dioxide nano-enzyme comprises the following steps: uniformly mixing an organic solution containing manganese nitrate hexahydrate with a montmorillonite aqueous solution to obtain a mixed reaction solution; the pH value of the mixed reaction solution is adjusted to be under the alkaline condition through alkali liquor, a synthetic reaction is carried out, then centrifugation and washing are carried out, the montmorillonite-loaded manganese dioxide nano-enzyme is obtained, and the manganese dioxide nano-enzyme is of a lamellar structure with the length being 20-400 nm. The manganese dioxide nano enzyme has excellent activity similar to superoxide dismutase, catalase and glutathione peroxidase; meanwhile, the compound also has the capability of removing various free radicals such as DPPH and ABTS, can be used for treating the inflammatory bowel disease, and has a wide application prospect.

The invention discloses a lactobacillus paracasei SX-M1559 strain and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation, and belongs to the technical field of microorganisms. The invention discloses a lactobacillus paracasei SX-M1559, and the preservation number of the lactobacillus paracasei SX-M1559 is CCTCC (China Center For Type Culture Collection) NO: M 2025030. According to the lactobacillus paracasei SX-M1559 and the application thereof in preparation of the medicine for reducing blood sugar, blood fat and inflammation, the SX-M1559 is separated from fresh feces of long-life old people, teai county, Zhanjiang city, Guangdong province, the glucose content in a zebra fish hyperglycemia model body and the fat content in a zebra fish hyperlipidemia model body can be remarkably reduced, and the effect of reducing blood sugar, blood fat and inflammation is achieved. The invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating hyperlipidemia, diabetes mellitus and inflammatory bowel disease by utilizing the new strain SX-M1559 of the casei paracasei.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention relates to bifidobacterium animalis subsp. Lactis C-2 with an effect of improving inflammatory bowel diseases and application of the bifidobacterium animalis subsp. Lactis C-2. The bifidobacterium animalis subsp. Lactis C-2 is classified and named as Bifidobacterium animalis subsp. Lactis, and the preservation number of the bifidobacterium animalis subsp. Lactis C-2 is GDMCC No: 65455. The bacterial strain can inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria and optimize the composition of intestinal microorganisms by regulating the intestinal microecology, repairing the intestinal mechanical barrier, improving the intestinal immune response, inhibiting oxidative stress reaction and other action mechanisms, thereby inducing anti-inflammatory response and improving the intestinal barrier function. Therefore, the bifidobacterium animalis subsp. Lactis C-2 strain is suitable for preparing the medicine with the effect of preventing, improving or treating the inflammatory bowel disease.

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention relates to the technical field of medicines, and discloses a mannose / trimethyl chitosan modified MXene material (MTC / MXene), a preparation method and application of the mannose / trimethyl chitosan modified MXene material in prevention and treatment of inflammatory bowel diseases. The MTC / MXene material is obtained by preparing mannose-modified trimethyl chitosan and modifying the mannose-modified trimethyl chitosan on a single-layer MXene nanosheet, compared with a pure MXene material, MTC modification endows MXene with hydrophilicity, rich reaction sites are provided for drug loading, higher oxidation resistance is achieved, meanwhile, through surface functional groups and interlayer gaps of the MXene material, the MXene / MTC / MXene material can be used for preparing the drug, and the drug loading efficiency is improved. Different types of drug molecules are loaded and are used for realizing targeted delivery and controlled release of drugs.

The invention discloses a lactobacillus plantarum strain from healthy people in a cold region and application of the lactobacillus plantarum strain. The lactobacillus plantarum strain is named as PL-H1, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22286. The lactobacillus plantarum PL-H1 screened by the invention can obviously relieve the disease index, intestinal canal pathological change, inflammatory response and the like of an inflammatory bowel disease (IBD) model mouse. Moreover, compared with a standard strain WCSF1, the strain has the high metabolism characteristic of tryptophan and the function of adjusting the metabolism of IBD host intestinal tryptophan, and the curative effect of preventing and treating IBD is more remarkable. In addition, the lactobacillus plantarum strain PL-H1 can also improve the liver lipid accumulation and NAFLD activity of MCD fed mice, improve the blood lipid level and liver injury of the MCD fed mice and prevent liver fibrosis of the MCD fed mice, can be used for preventing and treating fungal infection related diseases, and is good in safety.

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention discloses an application of probiotics Blauria winteriae in the preparation of a medicine or food for improving or treating the inflammatory bowel disease of children, and relates to the field of medicines or foods for improving or treating the inflammatory bowel disease of children. According to the invention, the probiotic Blauria wexlerae is used as an effective component to be prepared into medically and food acceptable dosage forms, so that the children inflammatory bowel disease can be obviously improved or treated, and the application value of the probiotic is improved.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

The invention discloses a health information management platform for an inflammatory bowel disease patient. The health information management platform comprises the following steps: step 1, user registration and information input; 2, data preprocessing and feature extraction; 3, constructing and training a model; step 4, a real-time prediction and early warning mechanism; according to the scheme, by actively monitoring the health data of the patient and applying the real-time analysis capability of the machine learning model, potential health problems can be recognized in advance, timely early warning is achieved, the risk of acute symptom attack is reduced, and therefore the life quality of the patient is improved, multi-dimensional data analysis is utilized, and the accuracy of the patient is improved. Customized health management suggestions are provided for each patient, individual requirements of the patient are met, the control ability of the patient to the illness state of the patient is enhanced, the treatment effect is improved, the system can provide more basis treatment suggestions for doctors through continuous learning and optimization, clinical decisions are helped to be improved, and the accuracy and effectiveness of overall treatment are improved.

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.

The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.

Compositions and methods for detecting gastrointestinal diseases are provided. The present invention relates to compositions and methods for detecting and treating gastrointestinal diseases. The present invention relates to the use of an agent for determining intestinal alkaline phosphatase (iAP) activity and the amount of iAP in a child for the preparation of a kit for use in a method for determining the prognosis of inflammatory bowel disease (IBD) in said child.

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).

The present disclosure provides methods of treating or preventing inflammatory bowel disease or sepsis in a subject by inhibiting SUMOylation in the subject.

The present disclosure provides a taxus mairei and analogues thereof useful in the treatment of inflammatory diseases or conditions (e.g., inflammatory bowel disease), as well as a pharmaceutical composition comprising the taxus mairei and analogues thereof, and methods of use and preparation thereof.

The invention belongs to the technical field of exosome preparation, and provides an extraction method of sea-buckthorn exosomes and application of the sea-buckthorn exosomes in relieving ulcerative bowel disease, fresh sea-buckthorn berries are cleaned and crushed, residues are filtered out, and juice is collected; carrying out primary centrifugal treatment on the juice, discarding precipitate and collecting supernatant; carrying out centrifugal treatment on the obtained supernatant again, discarding the precipitate and collecting the supernatant; carrying out third centrifugal treatment on the obtained supernatant, discarding the precipitate and collecting the supernatant; carrying out centrifugal treatment on the obtained supernate in an ultra-high-speed centrifuge to obtain exosome precipitates, and resuspending the exosome precipitates in a proper amount of precooled PBS (Phosphate Buffer Solution); according to the method, the high-purity hippophae rhamnoides exosome can be obtained through multi-stage centrifugation and sucrose gradient centrifugation, and the hippophae rhamnoides exosome has potential anti-inflammatory and anti-oxidation effects, can be used for treating inflammatory bowel diseases, can also be expanded to the field of treatment of other inflammatory diseases, and has wide application prospects.

The invention discloses lactobacillus kefiranofaciens and application thereof, and belongs to the technical field of microorganisms. The strain number of the lactobacillus kefiranofaciens is 2503, the lactobacillus kefiranofaciens is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the lactobacillus kefiranofaciens is CGMCC NO.33828. The lactobacillus kefiranofaciens is named as Lactobacillus kefiranofaciens. The lactobacillus kefiranofaciens provided by the invention is strong in acid resistance and bile salt resistance, has the functions of resisting oxidation and scavenging free radicals, can be planted in intestinal tracts, improves the abundance of beneficial bacteria in the intestinal tracts and reduces the abundance of pathogenic bacteria, and has good prevention and treatment effects on inflammatory bowel diseases.

The invention discloses a preparation method and application of a targeted delivery system of a metal polyphenol nano system. The invention discloses a targeted delivery system of a metal polyphenol nano system, and a preparation method of the targeted delivery system comprises the following steps: taking the metal polyphenol nano system formed based on epigallocatechin gallate and iron ions as a carrier, and loading fucoxanthin to prepare fucoxanthin nano particles with active oxygen response characteristics; then, after chondroitin sulfate capable of targeting macrophages and (5-carboxyl amyl) triphenyl phosphorus bromide capable of targeting mitochondria are coupled, the fucoxanthin delivery system with the active oxygen response characteristic and the targeting characteristic is further prepared through a double emulsion anti-solvent evaporation method. The system can realize release of fucoxanthin under stimulation of active oxygen, and realizes aggregation of a targeted delivery system in mitochondria of a specific inflammation site. The carrying system can effectively improve or relieve the inflammatory bowel disease, and the raw materials used in the carrying system are low in cost, the preparation conditions are mild, and large-scale production is easy.